发布求助
文献互助 智能选刊 最新文献

Future Prescriber最新文献

筛选
英文 中文
Technosphere: new drug delivery system for inhaled insulin 技术圈:新型吸入胰岛素给药系统
Future Prescriber Pub Date : 2012-07-11 DOI: 10.1002/fps.90
N Sarala, Girish Bengalorkar, K Bhuvana
{"title":"Technosphere: new drug delivery system for inhaled insulin","authors":"N Sarala,&nbsp;Girish Bengalorkar,&nbsp;K Bhuvana","doi":"10.1002/fps.90","DOIUrl":"10.1002/fps.90","url":null,"abstract":"<p>Injection has long since been a barrier to insulin use. However, previous attempts to produce an inhaled insulin have met with difficulty. Technosphere insulin is a new system for delivery of inhaled insulin and is currently under review by the FDA. In this Drug profile, the authors discuss the technology and review the clinical data relating to its efficacy and adverse effects. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 1","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2012-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.90","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84111955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Research misconduct: how bad is it and what can be done? 科研不端行为:有多严重?可以做些什么?
Future Prescriber Pub Date : 2012-07-11 DOI: 10.1002/fps.88
Steve Chaplin MSc, MRPharmS
{"title":"Research misconduct: how bad is it and what can be done?","authors":"Steve Chaplin MSc, MRPharmS","doi":"10.1002/fps.88","DOIUrl":"10.1002/fps.88","url":null,"abstract":"<p>We make two important assumptions when appraising the evidence behind an intervention: that the data are genuine and that they represent the total body of relevant knowledge. Doubts have been growing about both. Research misconduct and selective reporting of clinical trials are undermining confidence in scientific data, and the response of the research establishment has been mixed. Copyright © 2012 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"13 1","pages":"5-76"},"PeriodicalIF":0.0,"publicationDate":"2012-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.88","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75650049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Asenapine: novel antipsychotic for treatment of bipolar I disorder 阿塞那平:治疗双相I型障碍的新型抗精神病药
Future Prescriber Pub Date : 2012-01-03 DOI: 10.1002/fps.84
Delia Bishara BPharm, MSc, MCMHP, Eromona Whiskey BPharm, MCMHP, David Taylor MSc, PhD MRPharmS
{"title":"Asenapine: novel antipsychotic for treatment of bipolar I disorder","authors":"Delia Bishara BPharm, MSc, MCMHP,&nbsp;Eromona Whiskey BPharm, MCMHP,&nbsp;David Taylor MSc, PhD MRPharmS","doi":"10.1002/fps.84","DOIUrl":"10.1002/fps.84","url":null,"abstract":"<p><b>Asenapine is a new antipsychotic agent with activity for multiple receptors. It is administered sublingually for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. In this Drug profile the authors review the pharmacodynamic and pharmacokinetic properties of asenapine, and discuss its efficacy in bipolar I disorder and its likely positioning in clinical practice.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"5-9"},"PeriodicalIF":0.0,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.84","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77439629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dapagliflozin: a new possibility for managing type 2 diabetes 达格列净:治疗2型糖尿病的新可能性
Future Prescriber Pub Date : 2012-01-03 DOI: 10.1002/fps.86
Stephen Bain MA, MD, FRCP
{"title":"Dapagliflozin: a new possibility for managing type 2 diabetes","authors":"Stephen Bain MA, MD, FRCP","doi":"10.1002/fps.86","DOIUrl":"10.1002/fps.86","url":null,"abstract":"<p><b>Dapagliflozin is a new sodium-glucose transporter protein inhibitor under development for the treatment of type 2 diabetes mellitus. In this Drug profile, Professor Stephen Bain outlines why new treatments are needed, and considers the drug's efficacy and tolerability in clinical trials, to date, as well as its potential place in management.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"14-16"},"PeriodicalIF":0.0,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.86","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88057404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising developments in the treatment of cancer 癌症治疗方面有希望的进展
Future Prescriber Pub Date : 2012-01-03 DOI: 10.1002/fps.87
Jill Stein
{"title":"Promising developments in the treatment of cancer","authors":"Jill Stein","doi":"10.1002/fps.87","DOIUrl":"10.1002/fps.87","url":null,"abstract":"<p><b>The latest developments in the treatment of cancer were presented in September at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"17-19"},"PeriodicalIF":0.0,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.87","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77796417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunotherapy for treatment of advanced prostate cancer 免疫疗法治疗晚期前列腺癌
Future Prescriber Pub Date : 2012-01-03 DOI: 10.1002/fps.85
Simon J Hall MD
{"title":"Immunotherapy for treatment of advanced prostate cancer","authors":"Simon J Hall MD","doi":"10.1002/fps.85","DOIUrl":"10.1002/fps.85","url":null,"abstract":"<p><b>Prostate cancer is the most common cancer in men. Up to 30% of affected men will experience disease recurrence at some point, most of whom will be treated with hormone ablative therapy, which is effective for up to 90%. However, the effect is transient with the emergence of the castration-resistant phenotype. While secondary hormonal manipulations may result in temporary inhibition of disease progression, ultimately this is a fatal phenotype. This article looks at the emergence of two therapies that immunise against tissue-specific antigens in metastatic castrationresistant prostate cancer (mCRPC) to enhance survival.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 4","pages":"10-13"},"PeriodicalIF":0.0,"publicationDate":"2012-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.85","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86524537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bipolar I disorder: current and future management options 双相I型障碍:当前和未来的管理选择
Future Prescriber Pub Date : 2011-10-31 DOI: 10.1002/fps.82
Eduard Maron PhD, MD, Allan H Young PhD, MD, FRCPsych, FRCPC
{"title":"Bipolar I disorder: current and future management options","authors":"Eduard Maron PhD, MD,&nbsp;Allan H Young PhD, MD, FRCPsych, FRCPC","doi":"10.1002/fps.82","DOIUrl":"10.1002/fps.82","url":null,"abstract":"<p><b>Bipolar I disorder affects around one in every 100 adults and is a major public health issue. It is usually characterised by a combination of manic and depressive symptoms, with severe episodes of mood disturbance that can last for weeks or even months. Both men and women are affected, and the condition is a debilitating one that can adversely influence all areas of a person's life and his/her normal functioning. In this article, the authors look at the disease and its causes, and discuss both current and promising future treatment options.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 3","pages":"14-17"},"PeriodicalIF":0.0,"publicationDate":"2011-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.82","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87483474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Promising new inotropes for the treatment of heart failure 有希望的治疗心力衰竭的新肌力药物
Future Prescriber Pub Date : 2011-10-31 DOI: 10.1002/fps.81
Joanna Lumb
{"title":"Promising new inotropes for the treatment of heart failure","authors":"Joanna Lumb","doi":"10.1002/fps.81","DOIUrl":"10.1002/fps.81","url":null,"abstract":"<p><b>Positive news on the development of second-generation inotropes for treating heart failure was reported at the annual British Cardiovascular Society conference in June.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 3","pages":"10-11"},"PeriodicalIF":0.0,"publicationDate":"2011-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.81","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88780627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NSCLC: novel targeted therapies offer hope for the future 非小细胞肺癌:新型靶向治疗为未来带来希望
Future Prescriber Pub Date : 2011-10-31 DOI: 10.1002/fps.80
Marianne Nicolson MD, FRCP, Asa Dahle-Smith BSc, Mb ChB
{"title":"NSCLC: novel targeted therapies offer hope for the future","authors":"Marianne Nicolson MD, FRCP,&nbsp;Asa Dahle-Smith BSc, Mb ChB","doi":"10.1002/fps.80","DOIUrl":"10.1002/fps.80","url":null,"abstract":"<p><b>Lung cancer remains a major healthcare challenge despite the recent reduction in incidence in the Western world and introduction of the public smoking ban in some countries. However, the complexity of tumour biology is being unravelled along with a greater understanding of molecular signalling pathways, opening up a new field of research into targeted therapies. Here the authors focus on non-small cell lung cancer (NSCLC), discussing its current management and some of the promising targeted therapies currently being investigated.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 3","pages":"6-9"},"PeriodicalIF":0.0,"publicationDate":"2011-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.80","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77391509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Telaprevir: new specific protease inhibitor for chronic hepatitis C 特拉匹韦:治疗慢性丙型肝炎的新型特异性蛋白酶抑制剂
Future Prescriber Pub Date : 2011-10-31 DOI: 10.1002/fps.83
Geoffrey Dusheiko MB BCh FCP(SA) FRCP FRCP (edin)
{"title":"Telaprevir: new specific protease inhibitor for chronic hepatitis C","authors":"Geoffrey Dusheiko MB BCh FCP(SA) FRCP FRCP (edin)","doi":"10.1002/fps.83","DOIUrl":"10.1002/fps.83","url":null,"abstract":"<p><b>Current treatment for hepatitis C virus (HCV) genotype 1 infection with pegylated interferon (PEG-IFN) and ribavirin (RBV) is effective in less than 50% of patients. Retreatment with the same regimen is poorly effective. The advent of direct-acting antiviral agents that target replication of HCV promises to improve therapy for the disease. Telaprevir is a new protease inhibitor that specifically targets the NS3/4A serine protease, rapidly reducing HCV ribonucleic acid (RNA) levels. Several phase 2 and phase 3 studies have assessed the efficacy and safety of telaprevir. The author discusses the results of these studies, which suggest that the addition of this specific protease inhibitor to PEG-IFN-alpha2 and RBV can signifi cantly improve the results of treatment in patients affected with chronic HCV infection with genotype 1, compared with the standard treatment.</b> Copyright © 2011 John Wiley &amp; Sons, Ltd.</p>","PeriodicalId":100566,"journal":{"name":"Future Prescriber","volume":"12 3","pages":"19-23"},"PeriodicalIF":0.0,"publicationDate":"2011-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/fps.83","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76622378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信